Published in Am J Hum Genet on August 03, 2017
Genetics: Human genome editing in heart disease. Nat Rev Cardiol (2017) 0.75
Gene therapy: Human genome editing in heart disease. Nat Rev Genet (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol (2013) 18.01
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol (2013) 8.40
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell (2015) 7.80
Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell (2014) 6.11
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science (2015) 5.48
Procreative beneficence: why we should select the best children. Bioethics (2001) 4.70
Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol (2013) 4.58
Don't edit the human germ line. Nature (2015) 4.49
Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell (2013) 4.05
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature (2016) 3.54
Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell (2014) 3.16
Rationally engineered Cas9 nucleases with improved specificity. Science (2015) 3.14
Ethical and policy issues in genetic testing and screening of children. Pediatrics (2013) 3.03
Policy forum: genetics. Ethical considerations in synthesizing a minimal genome. Science (1999) 2.96
Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell (2014) 2.57
The legal concept of wrongful life. JAMA (1988) 2.11
Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev Biol (2014) 1.96
A mouse geneticist's practical guide to CRISPR applications. Genetics (2014) 1.81
Treatment decisions regarding infants, children and adolescents. Paediatr Child Health (2004) 1.71
Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res (2014) 1.58
ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Mol Ther (2015) 1.53
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Hum Genet (2015) 1.50
Should you edit your children's genes? Nature (2016) 1.46
History of gene therapy. Gene (2013) 1.42
Embryonic stem-cell research--the case for federal funding. N Engl J Med (2004) 1.40
Translating genomics in cancer care. J Natl Compr Canc Netw (2013) 1.35
International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reprod Biol Endocrinol (2014) 1.27
Mapping the integration of social and ethical issues in health technology assessment. Int J Technol Assess Health Care (2007) 1.19
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest (2014) 1.13
Eliciting ethical and social values in health technology assessment: A participatory approach. Soc Sci Med (2011) 1.08
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell (2016) 1.08
Facilitating family resilience with childhood illness and disability. Curr Opin Pediatr (2006) 1.07
A grand challenge: providing benefits of clinical genetics to those in need. Genet Med (2011) 0.98
Demographic differences in Down syndrome livebirths in the US from 1989 to 2006. Prenat Diagn (2011) 0.83
Genome editing in clinical genetics: points to consider-a statement of the American College of Medical Genetics and Genomics. Genet Med (2017) 0.78
Where in the world could the first CRISPR baby be born? Nature (2015) 0.78
Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Aff (Millwood) (2016) 0.77
Is there a moral obligation to select healthy children? J Med Ethics (2014) 0.77
GENETIC TECHNOLOGY REGULATION. Editing policy to fit the genome? Science (2016) 0.77